Amgen shared a post on X:
“Amgen’s LOCKTAC molecular glues are changing how we target disease.
AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.
Read more about how Amgen is working to innovate in this space.”
More posts featuring Amgen on OncoDaily.
